Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of “Hold” by Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given an average recommendation of “Hold” by the sixteen ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $32.4333.

Several brokerages recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday. Jefferies Financial Group set a $24.50 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Citigroup cut their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Truist Financial raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Friday, July 24th.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Management raised its full-year revenue outlook to approximately $3.1 billion–$3.3 billion, while second-quarter revenue increased 38% year over year to $753.2 million. The guidance suggests continued demand for Hims & Hers’ telehealth and weight-management offerings. Hims & Hers Raised Guidance
• Positive Sentiment: Bank of America and Needham analysts reportedly maintained constructive views on HIMS, supporting the bullish case that subscriber growth, expanding services, and the company’s longer-term healthcare platform can outweigh near-term volatility. Bank of America Analyst Forecast Needham Analyst Forecast
• Neutral Sentiment: Analyst opinion is divided: Citigroup issued a more pessimistic forecast, highlighting valuation and execution risks as Hims & Hers transitions its weight-loss business. Citigroup Forecast
• Negative Sentiment: The company’s gross margin fell six percentage points sequentially to 64% as branded GLP-1 drugs increased revenue but produced less favorable economics. The earnings report also included an adjusted loss of $0.37 per share, substantially below the $0.05 loss analysts expected, increasing concerns that growth is coming at the expense of profitability. Hims & Hers Margin Analysis
• Negative Sentiment: Several law firms, including Kaplan Fox, Kessler Topaz, Glancy Prongay Wolke, and Howard G. Smith, announced investigations into potential securities-law violations. These announcements are investor-solicitation notices rather than findings of wrongdoing, but they add headline, litigation, and reputational risk following the Federal Trade Commission’s lawsuit against the company. Kaplan Fox Investigation Kessler Topaz Investigation

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 7,573 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $30.25, for a total value of $229,083.25. Following the sale, the insider directly owned 11,280 shares of the company’s stock, valued at approximately $341,220. The trade was a 40.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells bought 48,400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was bought at an average cost of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the purchase, the director owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. The trade was a 27.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 83,126 shares of company stock worth $2,711,339 over the last quarter. 11.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of HIMS. Vanguard Group Inc. lifted its stake in shares of Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $11,187,000. Cunning Capital Partners LP purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $1,110,000. Norges Bank bought a new position in Hims & Hers Health in the 4th quarter valued at approximately $62,153,000. Finally, Virtu Financial LLC bought a new position in Hims & Hers Health in the 4th quarter valued at approximately $1,937,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $28.15 on Friday. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of -44.68 and a beta of 2.40. The business’s fifty day moving average is $32.11 and its 200 day moving average is $26.09. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $65.30. The company has a quick ratio of 1.56, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter last year, the company posted $0.17 EPS. Hims & Hers Health’s revenue for the quarter was up 38.2% compared to the same quarter last year. Research analysts expect that Hims & Hers Health will post -0.05 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.